Synjardy Receives EU Approval, Intensifying Competition in the Boehringer Ingelheim and Lilly Diabetes Combination Market
EU Approval and Product Composition
The European Commission granted marketing authorization for Synjardy as a treatment for type 2 diabetes on May 27, 2015. This followed the EMA's CHMP committee's positive opinion on March 26, 2015. Synjardy is a marketed, prescription fixed-dose combination product containing empagliflozin and metformin hydrochloride. The marketing authorization holder is Boehringer Ingelheim, and the product is part of the global diabetes co-development portfolio with Eli Lilly and Company (LLY). The U.S. FDA also approved Synjardy on August 26, 2015, establishing a regulatory presence in major Western markets.
Complementary Mechanisms and Clinical Evidence
Empagliflozin inhibits the sodium-glucose cotransporter 2 (SGLT2) in the renal proximal tubule, increasing glucose excretion in the urine. Metformin reduces glucose production in the liver and decreases intestinal absorption. The EMA's evaluation included three pivotal clinical trials involving 1,679 patients with type 2 diabetes whose condition was not adequately controlled with metformin alone or in combination with other diabetes medications. The primary endpoint was the reduction in glycated hemoglobin (HbA1c) at 24 weeks. The results showed that the combination of empagliflozin and metformin was superior to placebo and metformin, and had similar efficacy to the individual components. This represents a commercial strategy that combines two proven mechanisms into a single tablet, enhancing both glycemic control and patient compliance, rather than approving a novel molecule.
Competitive Landscape and Differentiation
The direct competitors are AstraZeneca's (AZN) Xigduo, a combination of dapagliflozin and metformin, and Janssen-Cilag's Vokanamet, a combination of canagliflozin and metformin. Both products received EU approval on January 16, 2014, and April 23, 2014, respectively, entering the market before Synjardy. The standard of care includes metformin, sulfonylureas, insulin, DPP-4 inhibitors, and GLP-1 receptor agonists. Prescription decisions are based not only on efficacy but also on cardiovascular and renal benefits, safety, reimbursement, and ease of administration. Synjardy aims to differentiate itself within the combination product category by combining empagliflozin's cardiovascular outcomes data with a fixed-dose formulation.
Market Potential and Investment Implications
The International Diabetes Federation estimates that diabetes-related healthcare costs in Europe will reach USD 193 billion in 2024, highlighting the economic scale of the indication. Eli Lilly's reported Jardiance product family sales were USD 3.432 billion in 2025, which includes Synjardy, Glyxambi, and Trijardy XR, and should be considered separately from single-product sales. Synjardy's approval allows Boehringer Ingelheim and Eli Lilly to expand the use of empagliflozin from a single agent to a combination product, capturing prescriptions across a patient's lifetime. However, due to the presence of established SGLT2 combination products and the growth of GLP-1 receptor agonists, the investment value will be determined by prescription retention rates, European reimbursement access, and the ability to defend the product family's sales, rather than the approval itself.
Synjardy is a marketed SGLT2/metformin combination product with both EU and U.S. FDA approval, serving as a means for Boehringer Ingelheim and Eli Lilly and Company (LLY) to expand their cardiovascular, renal, and metabolic franchises. The EMA's clinical evidence was obtained from 1,679 patients in three pivotal trials, and the fixed-dose formulation simplifies the prescription transition by adding empagliflozin to metformin-based therapy. In the short term, AstraZeneca's (AZN) Xigduo and Janssen-Cilag's Vokanamet, which were approved earlier in the EU, will be direct competitors. In the long term, the expansion of GLP-1 receptor agonists will put pressure on the market share of oral combination products. The USD 193 billion in European diabetes healthcare costs and the USD 3.432 billion in Jardiance product family sales in 2025 support the market potential, but the key to valuation lies in the fact that these are product family figures, not Synjardy's standalone performance.
Source: EMA (ema)